Implementing remote monitoring for COVID-19 patients in

primary care

- Svea Holtz^{1,a}, Susanne M. Köhler^{1,a,*}, Peter Jan Chabiera¹, Nurlan Dauletbaev^{2,3,4,5}, Kim
- Deutsch⁶, Zoe Oftring^{6,11}, Dennis Lawin⁷, Lukas Niekrenz⁸, Teresa Euler⁹, Rainer Gloeckl¹⁰,
- Rembert Koczulla¹⁰, Gernot Rohde⁹, Michael Dreher⁸, Claus F. Vogelmeier², Sebastian
- Kuhn^{6,11,a} and Beate Sigrid Müller^{1,12,a}
- ¹Goethe University Frankfurt, Institute of General Practice, 60590 Frankfurt am Main,
- Germany 8
- ² Department of Internal, Respiratory and Critical Care Medicine, Philipps University of
- Marburg, 35043 Marburg, Germany 10
- ³ Department of Pediatrics, McGill University, Montreal, QC H4A 3J1, Canada 11
- ⁴ The Research Institute of McGill University Health Centre, Montreal, QC H4A 3J1, Canada 12
- ⁵ al-Farabi Kazakh National University, Almaty 050040, Kazakhstan 13
- ⁶ Department of Digital Medicine, Medical Faculty OWL, Bielefeld University, 33615 14
- Bielefeld, Germany 15
- ⁷ Department of Cardiology and Intensive Care Medicine, University hospital OWL of 16
- Bielefeld University, Campus Klinikum Bielefeld, Bielefeld, Germany 17
- ⁸ Department of Pneumology and Intensive Care Medicine, University Hospital Aachen, 18
- 52074 Aachen, Germany 19
- ⁹ Goethe University Frankfurt, University Hospital, Medical Clinic 1, Department of 20
- Respiratory Medicine, 60590 Frankfurt am Main, Germany 21
- ¹⁰ Schoen Clinic Berchtesgadener Land, Institute for Pulmonary Rehabilitation Research,
- 83471 Schoenau am Koenigssee, Germany 23
- ¹¹ Institute of Digital Medicine, Philipps University of Marburg, 35043 Marburg, Germany 24
- ¹² Institute of General Practice, University of Cologne, Faculty of Medicine and University 25
- Hospital Cologne, 50937 Cologne, Germany 26
- *Correspondence: Dr. Susanne M. Köhler, Institut für Allgemeinmedizin, Theodor-Stern-Kai 27
- 7, 60590 Frankfurt am Main, Germany, koehler@allgemeinmedizin.uni-frankfurt.de 28
- a Note: All first authorship and shared last authorship eer review and should not be used to guide clinical practice. 29

Abstract

30

31

Background

- In Germany, most patients with coronavirus disease 2019 (COVID-19) are treated in an
- outpatient setting. To improve assessments of the health status of COVID-19 outpatients,
- various remote monitoring models have been developed. However, little information exists
- on experiences acquired with remote monitoring in an outpatient setting, particularly from a
- patient perspective. The aim of our 'COVID-19@home' study was therefore to implement
- and evaluate an app-based remote monitoring concept for acute and post-acute COVID-19-
- patients in primary care. In this paper, we focus on the patients' evaluation of our remote
- 39 monitoring approach.

Methods

40

- Patients with acute COVID-19 measured heart rate, blood pressure, oxygen saturation, and
- body temperature daily for 28 days. Patients with post-acute COVID-19 determined the
- same parameters for 12 weeks, supplemented by lung parameters and daily step count. The
- data were documented using the 'SaniQ' smartphone app. COVID-19 symptoms were
- assessed daily using an app-based questionnaire. Patients' GPs could access the data on the
- 46 'SaniQ Praxis' telemedicine platform. We used an app-based questionnaire consisting of 11
- 47 questions presented with a 4-point Likert scale to evaluate patient satisfaction. Data were
- 48 analyzed descriptively.

49 Results

- of the 51 patients aged 19-77 years that participated in the study, 42 completed the
- questionnaire. All patients rated home monitoring as 'very good' or 'rather good' and were
- able to integrate the measuring processes into their daily routines. Overall, 93% would
- recommend the app and the measuring devices to their family and friends. About 60% felt
- that their COVID-19 treatment had benefited from home monitoring. Only few patients were
- unsettled by the app and use of the measuring devices. During the course of the study, the
- 56 implementation process was optimized.

Conclusions

- 58 The use of remote monitoring in COVID-19 patients is feasible and was evaluated positively
- 59 by most study patients. However, it is difficult to imagine how general practices could cope
- with monitoring patients with acute diseases without any further organizational support.

- Future research should address cost-effectiveness and changes in such clinical outcomes as 61
- hospitalization and mortality. 62

Keywords 63

Primary Health Care; telemedicine; COVID-19; mobile applications; patient satisfaction

1. Introduction

65

In Germany, the majority of patients with a severe acute respiratory syndrome coronavirus 2 66 (SARS-CoV-2) infection are treated in an outpatient setting. This was true for 6/7 patients in 67 the first phase of the pandemic and thereafter for 32/33 patients, as a result of milder 68 disease courses in vaccinated patients [1]. While most patients present with mild or 69 moderate symptoms [2], some develop severe clinical outcomes and require hospitalization. 70 Despite receiving such treatment as invasive mechanical ventilation, or kidney replacement 71 therapy, some of these patients may die [3]. The early identification of patients showing 72 preliminary signs of deterioration is therefore crucial, since early interventions, including 73 hospitalization, are associated with better outcomes and prognoses [4]. Furthermore, the 74 severity of symptoms may not adequately reflect organ damage, especially as coronavirus 75 disease 2019 (COVID-19) is sometimes associated with 'silent hypoxia', an abrupt and 76 initially asymptomatic drop in oxygen saturation [5, 6]. Standardized monitoring of blood 77 oxygen saturation is expected to enable the timely recognition of patients requiring 78 treatment escalation [6-8]. 79 80 To better assess the health status of outpatients with COVID-19, health care providers in several countries reacted to the global outspread of SARS-CoV-2 by applying remote 81 monitoring solutions [9, 10]. Some providers, for example, used (video) phone-calls to gather 82 information, while others developed mobile applications (apps) to collect data on vital signs 83 [9]. However, both general practitioners and patients have little experience of using remote 84 monitoring for acute diseases [11]. 85 We therefore initiated the 'Covid-19@home' study, with the aim of implementing and 86 evaluating a remote monitoring concept for COVID-19-patients, i.e. patients with an acute 87 disease, in primary care. We used the 'SaniQ' app and the corresponding 'SaniQ Praxis' 88 telemonitoring platform [12]. In this paper, we focus on participating patients' adherence 89 and their evaluation of our approach to remote monitoring, as well as the optimization of 90 the implementation process.

2. Methods

91

92

Study design and setting 93

- We conducted a prospective observational study (COVID-19@home) in Frankfurt, Germany. 94
- The study was carried out from January to December 2021, whereby the period from 95

January 2021 to July 2021 was a pilot phase to optimize the implementation process. The

data presented in this study were collected between January and November 2021. For this

98 paper, we followed STROBE reporting guidelines for cohort studies, where applicable [13].

99 Study registration and ethical approval

100 COVID-19@home was part of the egePan Unimed project, and one of the thirteen projects

that make up 'Netzwerk Universitätsmedizin' [14]. It was registered in the German Clinical

102 Trials Register (DRKS00024604, https://www.drks.de/drks_web/setLocale_EN.do,

26.04.2021). The study was approved by the Ethics Committee of Goethe University

104 Frankfurt (No. 20-1023, 18.01.2021), and written informed consent was obtained from all

105 participants.

GPs

Eight GPs participated in the study. Seven of them belonged to a research network of general practices in Hesse, Germany (ForN) and were recruited after participating in a virtual network meeting. One GP agreed to participate after receiving an invitation to participate by mail. All GPs provided written informed consent prior to study participation. Qurasoft GmbH, Koblenz, Germany, provided each GP with his or her own password-protected user account for version 1.x of the SaniQ Praxis telemonitoring platform free of charge. Before recruiting patients, each GP attended a 30-minute one-on-one online training session on how to use the platform. The session was conducted by the software company Qurasoft GmbH using Microsoft Teams software. GPs did not receive any compensation for their participation.

Patients

Participating GPs asked patients that had had a PCR test for COVID-19 at their practice if they wished to participate. They were included in the study if their PCR test result was positive (acute COVID-19 patients). Patients that were being treated by their GPs for persistent COVID-19 symptoms (post-acute COVID-19 patients) were also asked if they wanted to participate. Patients had to be aged ≥ 18 years and have access to a smartphone that they, or someone in the same household, was able to use. GPs decided which patients to invite. They handed out a flyer that contained information on the study, and the phone number and email address of the study team. Patients could then contact the study team via telephone or email if they were interested in participating. The study team at the Institute of General Practice at Goethe University Frankfurt answered all questions by telephone.

Patients received detailed written study information and were required to give their written informed consent. They were also informed that neither the study team nor the treating GP provided 24/7-supervision, and that they were required to monitor their vital signs themselves. In case of medical queries, patients were advised to call their GPs or the emergency services. They were further required to confirm that they had understood these conditions on the consent form. Study participation was voluntary and could be terminated at any time. The patients received no monetary compensation but were permitted to keep the measuring devices.

Measuring devices and patient app

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

The patients received the required measuring equipment within 48 hours of inclusion in the study, so they could quickly begin monitoring their vital signs. Acute COVID-19 patients received a pulse oximeter, a blood pressure monitor, and a non-contact thermometer, while post-acute patients additionally received a peak flow and FEV1 meter, and an activity sensor (see table 1). Patients were also provided with two codes to activate and authorize the smartphone app 'SaniQ' (module 'Infekt'). All equipment was provided free of charge. After installing the app and entering the activation code, the patients used the devices to measure their health parameters. Data were entered into the app manually, or transmitted from the devices via Bluetooth®. The app was used to document the measured data and patients could view the data in the app (raw data and graphs), enabling them to monitor the course of the disease themselves. When a health parameter fell outside the normal range, the app sent an in-app notification or email to the patient (alert) stating that, for example, 'The measured value for your heart rate is outside the normal range. Please repeat the measurement. In case of uncertainty, contact your GP practice, or the emergency services.' During business hours, the study team could be reached on the telephone to answer questions that were unrelated to health. Additionally, the app and platform provider (Qurasoft GmbH) provided a hotline for technical problems.

Table 1. Measuring devices used in the study

154

155

156

157

158

159

160

161

162

163

164

165

Device	Image	Model
Pulse oximeter	[12]	Beurer PO 60 pulse oximeter, Beurer GmbH, Ulm, Germany
Blood pressure monitor	[12]	Aponorm Basis Plus Bluetooth, WEPA APOTHEKENBEDARF GmbH & Co KG, Montabaur, Germany
Non-contact thermometer	[12]	Beurer FT 95 non-contact thermometer, Beurer GmbH, Ulm, Germany
Peak flow and FEV1 meter	[12]	Smart One, MIR - Medical International Research s.r.l., Rome, Italy
Activity sensor	[12]	Beurer AS 99 Activity Tracker, Beurer GmbH, Ulm, Germany

Remote monitoring platform

By entering an authorization code, patients could link their account to their GP's 'SaniQ Praxis' account, thus permitting them to view their data. Developments in their vital signs were displayed as a list or graph. GPs decided individually – i.e. according to a patient's risk profile and the course of the disease - how often to check a patient's data. Upper and lower limits for the vital signs were defined in accordance with standard operating procedures (SOPs) of participating pneumology departments and the COVID-19 treatment recommendations available at the time [15] (see supplementary material table S.1). GPs could also tailor these predefined limits to suit the needs of individual patients. If a vital sign was outside the limits, the patient's GP received an automatic email from 'SaniQ Praxis' informing him or her accordingly. The GP could then check the available data on the

platform and contact the patient if necessary. The optional alarm function could be 166 deactivated by GPs for each individual patient. 167

Data collection

a. Measurements 169

168

172

179

180

181

183

184

187

188

190

191

192

195

170 For 28 days, acute patients measured their heart rate, blood pressure, SpO₂, and body temperature once a day. Post-acute patients determined the same vital signs for 12 weeks, 171

supplemented by lung parameters (peak flow [PEF], forced expiratory pressure in 1 second

[FEV1]) and activity parameters (daily step count). 173

b. Questionnaires 174

Patients filled in three in-app questionnaires consisting of questions relating to their medical 175

history, daily symptoms and views on remote monitoring: 176

The medical history questionnaire included questions on current COVID-19 symptoms, 177

relevant pre-existing medical conditions and current medication. Overall, the medical history 178

questionnaire consisted of 35 questions requiring yes or no answers (see supplementary

material table S.2) and was developed on the basis of available publications [16-19]. As the

pandemic was evolving rapidly and studies in an ambulatory setting were urgently needed,

the first patients were included while the questionnaire was still under development. The 182

study team therefore took the medical history of the first 22 patients by phone, and filled in

their medical history questionnaires retrospectively. In response to new research findings

(e.g. skin rashes), further questions on symptoms were added later. 185

The second questionnaire consisted of seven questions on the most common COVID-19 186

symptoms. It was based on the SOPs of participating pneumology departments, DEGAM

recommendations, and validated questionnaires on fatigue and shortness of breath [20–22].

Patients received the questionnaire daily for the duration of their participation in the study. 189

After completion of the study, patients were asked to fill in an evaluation questionnaire that

asked about their experiences and satisfaction with remote monitoring (see supplementary

material table S.3). The 11 questions were presented with a 4-point Likert scale and based

on validated questionnaires on telemedicine satisfaction and telehealth usability [23–26]. 193

Patients that stopped taking measurements before completing the study also received an 194

evaluation questionnaire and, if necessary, a telephone or email reminder at the end of the

study period. 196

Data analysis

A certified server hosted in Germany was used as an online platform to store all data. Patient data were exported from the platform in a comma-separated values (csv) format. Personal data were pseudonymized before analysis. We used Microsoft Excel 2016 to descriptively analyze the data. Continuous variables such as age are provided with their mean and standard deviation, while absolute and relative frequencies are provided for discrete data. The results also include information on the sample size n.

3. Results

Sample Characteristics

Overall, 51 outpatients participated in the COVID-19@home study, of whom 32 were acute COVID-19 patients and 19 post-acute patients. Patients were between 19 and 77 years old, and their mean age was 48.7 (SD: 12.5). Thirty women (58.8%) and 21 men (41.2%) participated. Eight (15.7%) patients were obese (body mass index 30 or more). Information on further pre-existing conditions were provided by 48 patients (94.1%), of whom 10 (20.8%) had one risk factor for a potentially severe course of COVID-19, eight (16.7%) had two, and three (6.3%) had three risk factors. Eight patients had cardiovascular disease (16.7%), while six each had diabetes mellitus or lung disease (12.5%). The patients reported a mean of 4.2 symptoms upon study inclusion (SD: 2.8, minimum: 0, maximum: 11) (see table 2).

Table 2. COVID-19 symptoms (n=50)

Acute patients			Post-acute	Post-acute patients		
n (total) ¹	n ²	%	n (total)¹	n ²	%	
31		100	19		100	
	o	0.0		7	36.8	
	10	32.3		4	21.1	
	13	41.9		6	31.6	
	7	22.6		2	10.5	
	1	3.2		0	0.0	
	n (total) ¹	n (total) ¹ n ² 31 0 10	n (total) ¹ n ² % 31 100 0 0.0 10 32.3 13 41.9 7 22.6	n (total) ¹ n ² % n (total) ¹ 31 100 19 0 0.0 10 32.3 13 41.9 7 22.6	n (total) ¹ n ² % n (total) ¹ n ² 31 100 19 7 10 32.3 4 13 41.9 6 7 22.6 2	

Lethargy/exhaustion	29	26	89.7	19	10	52.6
Headache/dizziness	10	8	80.0	19	7	36.8
Cough	31	23	74.2	19	4	21.1
Pain in muscles/joints	28	20	71.4	19	4	21.1
Difficulty concentrating	10	5	50.0	19	8	42.1
Head cold	29	12	41.4	19	3	15.8
Sore throat	30	12	40.0	19	3	15.8
Gastro-intestinal complaints	30	12	40.0	19	0	0.0
Fever/chills	31	11	35.5	19	1	5.3
Smell/taste impairment	30	11	36.7	19	6	31.6
Breathing difficulties	30	9	30.0	19	4	21.1
Chest pain	30	6	20.0	19	0	0.0
Skin rash	26	3	11.5	19	2	10.5

¹n (total): number of patients being asked about symptoms. Differences in n (total) reflect regular updates to the medical history questionnaire.

Participation

219

226

- Acute patients started taking measurements 1 to 26 days after receiving their positive PCR
- test result, or an average of 5.7 days (SD: 5.7). Patients with post-acute symptoms began 22
- to 447 days after receiving their positive PCR test result (mean: 152.4, SD: 112.6).
- Adherence to daily measuring was high, with 93.8% of acute patients and 89.5% of post-
- acute patients measuring vital signs as intended. The overall dropout rate was 7.8% (four
- patients).

Evaluation

- Overall, 48 patients received the evaluation questionnaire and 42 (87.5%) completed it. Of
- the respondents, 31 (73.8%) had 'rarely' or 'never' recorded their health data before.
- Nevertheless, 39 patients, or 92.9% 'completely agreed' or 'partially agreed' that they had
- managed to cope with using the app and measuring devices. All 42 respondents (100%)
- 'completely agreed' or 'partially agreed' that they 'could comfortably integrate
- measurement-taking' into their daily routines. Overall, 34 patients (81.0%) managed to deal
- with the app and devices on their own and 'rarely' or 'never' required aid in using them. Use

²n: number of patients with symptoms.

of the app and measuring devices rarely seemed to have unsettled users: 38 (90.5%) of our 234 cohort 'partially disagreed' or 'disagreed' that they had 'experienced uncertainty when using 235 the app and measuring devices'. 236 Twenty-five patients (59.5%) agreed that treatment of their COVID-19 illness had benefited 237 from remote monitoring. Patients' overall opinion of remote monitoring was very positive, 238 with all 42 respondents describing it as 'very good' or 'rather good' (100%). Moreover, 39 of 239 them (92.9%) would recommend the app and measuring devices to their family and friends 240 (see table 3 for more details). 241

Table 3. Evaluation of 'SaniQ' app and measuring devices (n = 42)

Questionnaire Item	n	%
Previous experience of recording healt	th data	l
Regularly	6	14.3
Sometimes	5	11.9
Rarely	8	19.0
Never	23	54.8
Coped with using the app and measur	ing devices	1
Completely agreed	30	71.4
Partially agreed	9	21.4
Partially disagreed	3	7.1
Completely disagreed	0	0
Easy integration into everyday life		1
Completely agreed	27	64.3
Partially agreed	15	35.7
Partially disagreed	0	0
Completely disagreed	0	0
Required aid in using the app and med	suring devices	<u>'</u>
Regularly	3	7.1
Sometimes	5	11.9
Rarely	6	14.3
		66.7

28.6
31.0
31.0
9.5
evices
0
9.5
23.8
66.7
<u> </u>
71.4
28.6
0
0
81.0
11.9
7.1
0

Changes to the implementation process

- 245 In order to include acute patients as quickly as possible the study team put on full protection
- gear to avoid infection and handed over the consent forms and measuring devices in person.
- 247 Afterwards, consent forms were returned via email. The measuring devices were sent to
- patients via express mail, as this proved to be reliable and fast enough (delivery within 48
- 249 hours).

243

- 250 We also distributed a detailed manual provided by the software partner, which resulted in a
- 251 sharp drop in the number of calls due to technical problems.
- 252 As the pandemic was evolving rapidly and studies were urgently needed in an ambulatory
- setting, we started enrolling patients in January 2021, even though the development of our
- in-app questionnaires had not yet been finalized. During the pilot phase, we took patients'
- 255 medical histories and gathered information on their COVID-19 symptoms by telephone.

- Further questions on symptoms were added when new research findings were published
- 257 (e.g. gastro-intestinal complaints, skin rashes). The evaluation questionnaire was presented
- 258 to 48/51 patients.

259

260

268

4. Discussion

Main findings

- 261 We implemented a remote monitoring concept for COVID-19 outpatients. Patients used the
- 262 included app to self-monitor their vital parameters and symptoms daily. GPs could then view
- the results on a software platform. Patient adherence was high with 93.8% of acute patients
- and 89.5% of post-acute patients measuring vital signs as intended. All patients that
- completed an evaluation questionnaire rated the app as 'very good' or 'rather good'. Almost
- all patients would recommend the app and measuring devices to their families and friends.
- ²⁶⁷ We optimized the implementation process during the pilot phase.

Findings in relation to the literature

- Our study is one of only a few to focus on patients' use of remote monitoring to
- communicate with their GP practice [27]. In contrast to other studies and in order to gain
- broad experience, we included patients of all ages and with any pre-existing conditions.
- 272 Several studies on remote monitoring have, however, investigated COVID-19 patients that
- 273 required ongoing supervision and treatment in secondary settings, such as pre-admission
- wards, virtual wards, or that were receiving care in a 'hospital at home' (following an early
- release from hospital) [9, 28, 29]. Some studies included all patients suspected of having
- 276 COVID-19, regardless of their PCR test results [30]. In our study, however, a positive PCR
- 277 result was an inclusion criterion, which allowed us to focus on COVID-19 patients and their
- specific needs (e.g., self-isolation at home).
- 279 International studies on remote monitoring generally used pulse oximetry, while only a few
- used non-contact thermometers and blood pressure monitors [9, 28]. Telephone-, app- and
- paper-based protocols were used for data transfer [9, 28, 31, 32]. We decided to use an app
- to ensure instant documentation and data transfer, a low risk of transmission errors, and
- greater opportunities for data analysis. We managed to enrol acute COVID-19 patients
- quickly, and included them in our study a median of 3.5 days after a positive PCR test result.
- 285 While other studies also emphasized the importance of speed, they provided no exact
- 286 enrolment data [9].

Several authors have concluded that remote monitoring cannot be successful unless patients' needs are taken into account [7, 28]. A lack of patient training, technical barriers, and insufficient usability appear to explain most patient dropouts [11, 28, 33]. In our study, some patients experienced initial difficulties installing the app and connecting the measuring devices. We therefore added a detailed manual to emails and packages containing the devices. This resulted in a sharp drop in the number of calls due to technical problems, and the overall dropout rate was low (7.8%). Patients' evaluations indicate that our remote monitoring concept is suitable for patients that have no experience of recording health data. However, patients without German language skills could not participate in our remote monitoring program, unlike some remote home monitoring models in the UK that developed culturally appropriate patient information in different languages [28]. Our patients were advised to monitor their vital signs 'at least once a day'. However, the frequency with which they measured them varied. This complicated data management, analysis and interpretation. We would therefore recommend specifying frequency more precisely in future studies. It might also be appropriate to adjust the frequency of measurements over the course of the disease and to intensify it in high-risk acute COVID-19 patients, as was the case in a study on remote monitoring conducted in Tuscany [34]. To raise compliance, post-acute patients might also be asked to take their measurements less

Strengths and limitations

often, e. g. three times a week.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

Despite the relatively small sample size, our study provides real-world experience from 307 patients who used the app intensively over a long period of time. They were thus able to 308 accumulate considerable experience of remote monitoring, which increased the informative 309 value of our evaluation results. 310 However, our study also has several limitations. As our questionnaires were still under 311 development when the pilot phase began, they were partially conducted on the telephone 312 313 and partially via the app itself. Furthermore, the medical history questionnaire evolved throughout the study to take account of new scientific findings on COVID-19 symptoms, 314 limiting the generalizability of our results. In addition, we did not use a validated 315 questionnaire, and several adjustments were made to the implementation process during 316 the course of the study. At the beginning of the study, for example, we wore full protective 317 gear to avoid infection and provided the consent forms and measuring devices in person. 318

Afterwards, consent forms were distributed and collected via email, and measuring devices 319 were sent to patients using express mail. As a result, the processes assessed by the patients 320 were not identical, which may have limited the validity of our results. 321 However, as these modifications mainly concerned organizational processes, and the self-322 monitoring process remained unchanged, we would expect their influence on the evaluation 323 to have been small. As quarantine limited technical support options, our approach to remote 324 monitoring was only suitable for patients that owned a smartphone and were familiar with 325 installing and using apps. It was therefore impossible to include persons that were unable to 326 use the technical infrastructure. This also applied to people with language barriers or 327 disabilities that would have prevented them from using the app and devices. In future 328 research, attempts should be made to make remote monitoring possible for these people, 329 too. Future research should also address cost-effectiveness and changes in such clinical 330 outcomes as hospitalization and mortality, which we did not consider. 331

5. Conclusion

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

In this study, we implemented remote monitoring among COVID-19 outpatients and iteratively optimized our approach during a pilot phase. During the implementation process, we learned that the success of remote monitoring depends on certain conditions being fulfilled. First, non-contact delivery of measuring devices should be arranged for acute COVID-19 patients as soon as possible after the disease is diagnosed. Second, patients need precise and comprehensive instructions on how to correctly install and use the app and measuring devices. Patients' evaluations indicate that most patients then accepted and were able to use remote monitoring as we intended. Third, as some patients initially experienced technical difficulties, background support was required to ensure both patient adherence and that the system worked as planned. However, it is difficult to imagine how general practices could cope with these additional tasks. Sufficient patient and practice support should therefore be provided if the model is to be implemented on a larger or even nationwide scale.

Acknowledgments

The authors would like to express their thanks to all participating patients and GPs. We are also grateful to Phillip Elliott for the language review of the paper.

Funding

349

352

- 350 This research was funded by the German Federal Ministry of Education and Research, BMBF,
- grant number 01KX2021.

Competing interest statement

- The institutions of S.H., S.M.K., P.J.C., N.D., L.N., T.E., R.G., R.K., G.R., M.D., C.F.V. and B.S.M
- 354 received funding for this study from the German Federal Ministry of Education and
- Research, BMBF, grant number 01KX2021. The funder had no role in the design of the study;
- in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in
- the decision to publish the results. P.J.C. is an employee at OncologyInformationService e.K.
- N.D. has received the CSL Behring award 'Translational Research on Extracellular Vesicles in
- 359 COPD'. R.K. and R.G. have been involved in projects and publications using the Kaia COPD
- App. SK is founder and managing partner of MED.digital GmbH. He holds shares of BioNTech,
- ³⁶¹ Pfizer, and CRISPR Therapeutics. He is member of the commission 'New Professions' of
- 362 Stiftung Münch and of several committees of the German Medical Association
- ('Digitalization of health care' and 'Medical Education and University Medicine'). B.S.M. has
- 364 received personal honoraria for scientific consultancy to health insurance fund 'Die
- Techniker'. The remaining authors declare no conflict of interest.

366 Availability of data and materials

- The datasets generated and analyzed during the study are available from the corresponding
- 368 author on reasonable request.

References

- 1. KBV. Ambulante Versorgung in der Corona-Pandemie.
- https://www.kbv.de/media/sp/Ambulante_Versorgung_Corona_Pandemie_Zahlen_Fakt
- en.pdf. Accessed 9 Nov 2022.
- 2. Neef V, Piekarski F, Zacharowski K, Raimann FJ. SARS-CoV-2-Pandemie eine Meta-
- Analyse zur Klinik, Diagnostik und Therapie der Infektion. Anästh Intensivmed.
- 2020;61:480–91. doi:10.19224/ai2020.480.
- 376 3. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients

- Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323:2052–9.
- 379 doi:10.1001/jama.2020.6775.
- 380 4. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med.
- 381 2020;383:1757–66. doi:10.1056/NEJMcp2009249.
- 5. Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ. Silent hypoxia in COVID-
- 19: pathomechanism and possible management strategy. Mol biol rep. 2021;48:3863–9.
- doi:10.1007/s11033-021-06358-1.
- 385 6. Levitan RM. Pulse Oximetry as a Biomarker for Early Identification and Hospitalization of
- 386 COVID-19 Pneumonia. Acad Emerg Med. 2020;27:785–6. doi:10.1111/acem.14052.
- 7. Greenhalgh T, Knight M, Inda-Kim M, Fulop NJ, Leach J, Vindrola-Padros C. Remote
- management of covid-19 using home pulse oximetry and virtual ward support. BMJ.
- 389 2021;372:n677. doi:10.1136/bmj.n677.
- 390 8. Shah S, Majmudar K, Stein A, Gupta N, Suppes S, Karamanis M, et al. Novel Use of Home
- Pulse Oximetry Monitoring in COVID-19 Patients Discharged From the Emergency
- Department Identifies Need for Hospitalization. Acad Emerg Med. 2020;27:681–92.
- 393 doi:10.1111/acem.14053.
- 9. Vindrola-Padros C, Singh KE, Sidhu MS, Georghiou T, Sherlaw-Johnson C, Tomini SM, et
- al. Remote home monitoring (virtual wards) during the COVID-19 pandemic: a
- systematic review. medRxiv. 2020:2020.10.07.20208587.
- 397 doi:10.1101/2020.10.07.20208587.
- 10. Bokolo AJ. Use of Telemedicine and Virtual Care for Remote Treatment in Response to
- 399 COVID-19 Pandemic. J Med Syst. 2020;44:132. doi:10.1007/s10916-020-01596-5.
- 400 11. Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Interactive telemedicine: effects
- on professional practice and health care outcomes. Cochrane Database Syst Rev.
- 402 2015:CD002098. doi:10.1002/14651858.CD002098.pub2.
- 403 12. SaniQ. 2022. https://saniq.org/. Accessed 22 Mar 2022.
- 13. Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
- statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–
- 9. doi:10.1016/j.jclinepi.2007.11.008.

- 408 14. Netzwerk Universitätsmedizin. Projekte. Forschungsarbeiten für die bestmögliche
- Patientenversorgung. 2022. https://www.netzwerk-universitaetsmedizin.de/. Accessed
- 410 5 Dec 2022.
- 15. Greenhalgh T, Thompson P, Weiringa S, Neves AL, Husain L, Dunlop M, et al. What items
- should be included in an early warning score for remote assessment of suspected
- 413 COVID-19? qualitative and Delphi study. BMJ Open. 2020;10:e042626.
- doi:10.1136/bmjopen-2020-042626.
- 16. Hüfner A, Kiefl D, Baacke M, Zöllner R, Loza Mencía E, Schellein O, et al.
- 416 Risikostratifizierung durch Implementierung und Evaluation eines COVID-19-Scores : Eine
- retrospektive Diagnostikstudie. [Risk stratification through implementation and
- evaluation of a COVID-19 score: A retrospective diagnostic study]. Med Klin Intensivmed
- Notfmed. 2020;115:132–8. doi:10.1007/s00063-020-00754-4.
- 17. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of
- 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical
- Characterisation Protocol: prospective observational cohort study. BMJ.
- 2020;369:m1985. doi:10.1136/bmj.m1985.
- 18. Brian E. Dixon, Kara Wools-Kaloustian, William F. Fadel, Thomas J. Duszynski, Constantin
- Yiannoutsos, Paul K. Halverson, Nir Menachemi. Symptoms and symptom clusters
- associated with SARS-CoV-2 infection in community-based populations: Results from a
- statewide epidemiological study.
- 19. Patienten-Info zum Coronavirus (SARS-CoV-2): Symptom-Checkliste für SARS-CoV-2.
- 429 07.06.2022. https://thieme-
- 430 compliance.de/fileadmin/user upload/Download/Informationsmaterialien/Coronavirus/
- de/symptomchecker.html. Accessed 23 Nov 2022.
- 432 20. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP.
- Development of a fatigue scale. Journal of Psychosomatic Research. 1993;37:147–53.
- 434 doi:10.1016/0022-3999(93)90081-P.
- 21. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea
- measure: the UCSD Shortness of Breath Questionnaire. University of California, San
- Diego. Chest. 1998;113:619–24. doi:10.1378/chest.113.3.619.
- 22. DEGAM. SARS-CoV-2/-Covid-19-Informationen & Praxishilfen für niedergelassene
- Hausärztinnen und Hausärzte: S2e-Leitlinie. 2022.

- https://register.awmf.org/assets/guidelines/053-054l S2e SARS-CoV-2-Covid-19-
- Informationen-Praxishilfen-Hausaerztinnen-Hausaerzte_2022-02_2.pdf. Accessed 5 Dec
- 442 **2022**.
- 23. Finkelstein SM, MacMahon K, Lindgren BR, Robiner WN, Lindquist R, VanWormer A,
- Hertz MI. Development of a remote monitoring satisfaction survey and its use in a
- clinical trial with lung transplant recipients. J Telemed Telecare. 2012;18:42–6.
- 446 doi:10.1258/jtt.2011.110413.
- 24. PARMANTO B, LEWIS AN, GRAHAM KM, BERTOLET MH. Development of the Telehealth
- 448 Usability Questionnaire (TUQ). Int J Telerehabil. 2016;8:3–10. doi:10.5195/ijt.2016.6196.
- 25. Ruiz Díaz MA, Egea García M, Muñoz Aguilera R, Viñolas Prat X, Silvestre García J, Álvarez
- Orozco M, Martínez Ferrer J. Patient satisfaction with remote monitoring of cardiac
- implantable electronic devices: the VALIOSA questionnaire. BMC Health Serv Res.
- 452 2020;20:354. doi:10.1186/s12913-020-05216-3.
- 26. Yip MP, Chang AM, Chan J, MacKenzie AE. Development of the Telemedicine Satisfaction
- 454 Questionnaire to evaluate patient satisfaction with telemedicine: a preliminary study. J
- Telemed Telecare. 2003;9:46–50. doi:10.1258/135763303321159693.
- 456 27. Wurzer D, Spielhagen P, Siegmann A, Gercekcioglu A, Gorgass J, Henze S, et al. Remote
- 457 monitoring of COVID-19 positive high-risk patients in domestic isolation: A feasibility
- study. PLoS One. 2021;16:e0257095. doi:10.1371/journal.pone.0257095.
- 459 28. Vindrola-Padros C, Sidhu MS, Georghiou T, Sherlaw-Johnson C, Singh KE, Tomini SM, et
- al. The implementation of remote home monitoring models during the COVID-19
- pandemic in England. EClinicalMedicine. 2021;34:100799.
- doi:10.1016/j.eclinm.2021.100799.
- 29. Motta LP, Da Silva PPF, Borguezan BM, Amaral JLMd, Milagres LG, Bóia MN, et al. An
- emergency system for monitoring pulse oximetry, peak expiratory flow, and body
- temperature of patients with COVID-19 at home: Development and preliminary
- application. PLoS One. 2021;16:e0247635. doi:10.1371/journal.pone.0247635.
- 30. Dirikgil E, Roos R, Groeneveld GH, Heringhaus C, Silven AV, Petrus AHJ, et al. Home
- 468 monitoring reduced short stay admissions in suspected COVID-19 patients: COVID-box
- project. Eur Respir J. 2021;58:2100636. doi:10.1183/13993003.00636-2021.

- 31. Yordanov Y, Dechartres A, Lescure X, Apra C, Villie P, Marchand-Arvier J, et al. Covidom, 470
- a Telesurveillance Solution for Home Monitoring Patients With COVID-19. J Med Internet 471
- Res. 2020;22:e20748. doi:10.2196/20748. 472
- 32. Schinköthe T, Gabri MR, Mitterer M, Gouveia P, Heinemann V, Harbeck N, Subklewe M. 473
- A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: 474
- Qualitative Study and Application Development. JMIR Public Health Surveill. 475
- 2020;6:e19033. doi:10.2196/19033. 476
- 33. Bardy P. The Human Challenge of Telemedicine: Toward a Time-Sensitive and Person-477
- Centered Ethics of Home Telecare. San Diego: ISTE Press Limited Elsevier Incorporated; 478
- 2018. 479
- 34. Panicacci S, Donati M, Lubrano A, Vianello A, Ruiu A, Melani L, et al. Telemonitoring in 480
- the Covid-19 Era: The Tuscany Region Experience. Healthcare. 2021;9:516–27. 481
- doi:10.3390/healthcare9050516. 482